Identification | Back Directory | [Name]
YF438 | [CAS]
2247210-09-7 | [Synonyms]
YF438 Heptanediamide, N7-hydroxy-N1-(4-methoxyphenyl)-N1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]- | [Molecular Formula]
C23H26N4O5 | [MOL File]
2247210-09-7.mol | [Molecular Weight]
438.48 |
Hazard Information | Back Directory | [Uses]
YF438 is an HDAC inhibitor with effective anticancer activity both in vitro and in vivo. YF438 inhibits the growth and metastasis of triple-negative breast cancer (TNBC) cells by blocking the interaction between HDAC and MDM2, inducing the dissociation of MDM2-MDMX, and promoting the degradation of MDM2[1]. | [References]
[1] Shan P, et al. Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer. Cancer Res. 2021 Aug 1;81(15):4027-4040. DOI:10.1158/0008-5472.CAN-20-0922 |
|
|